Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Emergent BioSolutions Inc.

NYSE: EBS · Life Sciences · 7 alerts · CIK 1367644

Share price
$5.81Close, Nov 16
Market cap
$299M
Shares outstanding
51.42MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Emergent BioSolutions Inc. filings on SEC EDGAR ↗

4:08 PM ET 8-K
Contract Win

Emergent BioSolutions Wins $22.3M Contract from U.S. Department of War

Emergent BioSolutions received a $22.3 million modification exercising an option under an existing IDIQ contract to supply BioThrax (Anthrax Vaccine Adsorbed) to the U.S. Department of War. Deliveries will begin in 2026 with a $7.4 million initial shipment and continue through 2027 to support anthrax pre-exposure prophylaxis for all branches of the U.S. military.

Value
$22.3M
Counterparty
U.S. Department of War
Term
through 2027
6:00 AM ET 10-Q
Financial Results

Emergent BioSolutions Q3 2026 Results: Net Loss of $32.7M

Emergent BioSolutions reported total assets of $995.2 million as of September 30, 2026, a decrease from $1,318.6 million at year-end 2025. The company is navigating significant debt obligations under a new 2026 Term Loan Agreement and is focused on its medical countermeasure (MCM) contracts with the U.S. government and the commercial performance of NARCAN Nasal Spray.

Key figure
Net loss $32.7M
4:07 PM ET 8-K
Financial Results

Emergent BioSolutions Financial Results

Emergent BioSolutions reported Q3 2026 total revenues of $110.0 million, a 52% decrease year-over-year, and a net loss of $32.7 million. The results were primarily driven by the company's biodefense and naloxone portfolios as it continues a multi-year strategic transformation and turnaround.

Term
Q3 2026

“Emergent's third-quarter results, which include revenue of $110.0 million inline with our guidance, were primarily driven by our diverse biodefense/medical countermeasures and naloxone portfolio, underscoring the importance of disciplined execution as we advance our multi-year transformation.”

Joe Papa, president and chief executive officer

“We remain focused on our turnaround priorities and strengthening our financial position, which includes improving operating performance, reducing debt, creating long-term shareholder value, continuously demonstrating high standards of quality and compliance in all we do and delivering on our mission to protect and save lives.”

Joe Papa, president and chief executive officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.